Grassley Invites HHS IG to Testify on EpiPen’s CMS Misclassification

Drug Industry Daily
A A
Sen. Chuck Grassley (R-Iowa) is continuing his investigation into Mylan’s ballooning pricing of the EpiPen and government rebates that it has received, requesting more information in the latest of a series of letters to manufacturer and several federal agencies.

To View This Article:

Login

Subscribe To Drug Industry Daily